Heartland Advisors Inc. Has $7.57 Million Stock Position in Accuray Incorporated (NASDAQ:ARAY)

Heartland Advisors Inc. lifted its holdings in shares of Accuray Incorporated (NASDAQ:ARAY) by 14.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,824,750 shares of the medical equipment provider’s stock after purchasing an additional 472,800 shares during the period. Heartland Advisors Inc.’s holdings in Accuray were worth $7,573,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Accuray by 489.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 277,859 shares of the medical equipment provider’s stock worth $500,000 after buying an additional 230,695 shares during the period. Jacobs Levy Equity Management Inc. lifted its stake in shares of Accuray by 143.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 384,944 shares of the medical equipment provider’s stock worth $693,000 after acquiring an additional 226,602 shares during the period. JPMorgan Chase & Co. boosted its holdings in Accuray by 482.4% in the fourth quarter. JPMorgan Chase & Co. now owns 242,713 shares of the medical equipment provider’s stock valued at $481,000 after acquiring an additional 201,037 shares during the last quarter. XTX Topco Ltd bought a new position in Accuray during the 3rd quarter worth approximately $249,000. Finally, BNP Paribas Financial Markets lifted its position in shares of Accuray by 1,650.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 146,384 shares of the medical equipment provider’s stock worth $263,000 after purchasing an additional 138,022 shares during the period. Institutional investors own 64.08% of the company’s stock.

Accuray Stock Performance

ARAY stock opened at $1.82 on Friday. The firm has a market cap of $187.15 million, a PE ratio of -36.40 and a beta of 1.46. The company has a current ratio of 1.62, a quick ratio of 0.88 and a debt-to-equity ratio of 3.51. The stock has a 50-day moving average price of $2.09 and a 200-day moving average price of $1.99. Accuray Incorporated has a 1-year low of $1.40 and a 1-year high of $2.95.

Accuray (NASDAQ:ARAY) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.03. Accuray had a negative return on equity of 9.75% and a negative net margin of 0.96%. As a group, equities research analysts expect that Accuray Incorporated will post 0.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut shares of Accuray from a “buy” rating to a “hold” rating in a research report on Saturday.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.